Cite
HARVARD Citation
Bess, S. et al. (n.d.). 151 Intermediate Dosing of Recombinant Human Bone Morphogenetic Protein-2 Improves Fusion Rates With No Increase in Major Complications but Does Not Improve Health Related Quality of Life for Adult Spinal Deformity at Minimum 2 Years: A Prospective, Multicenter Analysis. Neurosurgery. pp. 209-210. [Online].